ATE486874T1 - Purinonderivate als hm74a-agonisten - Google Patents

Purinonderivate als hm74a-agonisten

Info

Publication number
ATE486874T1
ATE486874T1 AT07798941T AT07798941T ATE486874T1 AT E486874 T1 ATE486874 T1 AT E486874T1 AT 07798941 T AT07798941 T AT 07798941T AT 07798941 T AT07798941 T AT 07798941T AT E486874 T1 ATE486874 T1 AT E486874T1
Authority
AT
Austria
Prior art keywords
hm74a agonists
purinone derivatives
purinone
derivatives
hm74a
Prior art date
Application number
AT07798941T
Other languages
English (en)
Inventor
Brian Metcalf
Ke Zhang
Changsheng Zheng
Chu-Biao Xue
Ganfeng Cao
Anlai Wang
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Application granted granted Critical
Publication of ATE486874T1 publication Critical patent/ATE486874T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT07798941T 2006-06-23 2007-06-22 Purinonderivate als hm74a-agonisten ATE486874T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81593506P 2006-06-23 2006-06-23
US92292407P 2007-04-11 2007-04-11
PCT/US2007/071895 WO2007150026A2 (en) 2006-06-23 2007-06-22 Purinone derivatives as hm74a agonists

Publications (1)

Publication Number Publication Date
ATE486874T1 true ATE486874T1 (de) 2010-11-15

Family

ID=38705054

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07798941T ATE486874T1 (de) 2006-06-23 2007-06-22 Purinonderivate als hm74a-agonisten

Country Status (14)

Country Link
US (3) US7462624B2 (de)
EP (1) EP2049544B9 (de)
JP (2) JP5274455B2 (de)
KR (1) KR20090025262A (de)
AR (1) AR061626A1 (de)
AT (1) ATE486874T1 (de)
AU (1) AU2007260852B2 (de)
CA (1) CA2656002A1 (de)
DE (1) DE602007010312D1 (de)
IL (1) IL195896A0 (de)
MX (1) MX2009000169A (de)
NO (1) NO20085099L (de)
TW (1) TWI423978B (de)
WO (1) WO2007150026A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
AR061625A1 (es) * 2006-06-23 2008-09-10 Incyte Corp Derivados de purinona como agonistas de hm74a
ATE486874T1 (de) * 2006-06-23 2010-11-15 Incyte Corp Purinonderivate als hm74a-agonisten
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009144548A1 (en) * 2008-05-28 2009-12-03 Glenmark Pharmaceuticals S.A. Imidazo [2,1-b] purine derivatives as trpa1 modulators
US20120316176A1 (en) * 2009-12-22 2012-12-13 Deen Tulshian DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b] PURIN-4(5H)-ONE and METHODS OF USE THEREOF
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2015131783A (ja) * 2014-01-14 2015-07-23 株式会社日本ファインケム アリール−１，２，４−トリアゾール誘導体の製造方法
SG11201705889VA (en) * 2015-01-30 2017-08-30 Shanton Pharma Co Ltd Prevention or Treatment of Uratic or Gouty Diseases
WO2018038340A2 (en) 2016-08-24 2018-03-01 Samsung Electronics Co., Ltd. Electronic device including light-emitting elements and method of operating electronic device
WO2020045558A1 (ja) * 2018-08-30 2020-03-05 テラ・ストーン株式会社 キサンチンオキシダーゼを阻害するためのヒドラジノプリン化合物及びトリアゾロプリン化合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404380A (en) 1977-02-14 1983-09-13 Mead Johnson & Company Triazolopyrimidines
US5132424A (en) 1988-07-21 1992-07-21 The Upjohn Company Pyrazolo-pyrrolo-pyrimidine-diones
ATE145908T1 (de) * 1989-09-14 1996-12-15 Kyowa Hakko Kogyo Kk 5-triazolo(3,4-i)purinderivate
JP2002508660A (ja) 1997-06-12 2002-03-19 スミスクライン ビーチャム コーポレーション Ｈｍ７４ａ受容体
WO2000001388A1 (en) * 1998-07-02 2000-01-13 Kyowa Hakko Kogyo Co., Ltd. Remedies for diabetes
ES2238335T3 (es) 1999-12-24 2005-09-01 Kyowa Hakko Kogyo Co., Ltd. Derivados de purina condensados.
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
UA75625C2 (en) 2000-12-01 2006-05-15 Biogen Inc Condensed purine derivatives as a1 adenosine receptor antagonists
US20040254224A1 (en) * 2001-04-11 2004-12-16 Foord Steven Michael Medicaments
UA80258C2 (en) 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
WO2004071378A2 (en) 2003-02-17 2004-08-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
HRP20130406T1 (hr) * 2004-02-14 2013-06-30 Glaxosmithkline Intellectual Property Development Limited Medikamenti s aktivnošä†u prema receptoru hm74a
US20060078916A1 (en) * 2004-08-27 2006-04-13 Luc Aguilar HM74 and HM74a in cuboidal endothelial cells as associated with inflammation
JP2008517029A (ja) 2004-10-22 2008-05-22 スミスクライン・ビーチャム・コーポレイション Ｈｍ７４ａ受容体活性を有するキサンチン誘導体
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
GB0516462D0 (en) 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
JP5112316B2 (ja) 2005-08-10 2013-01-09 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体
ATE486874T1 (de) 2006-06-23 2010-11-15 Incyte Corp Purinonderivate als hm74a-agonisten
AR061625A1 (es) 2006-06-23 2008-09-10 Incyte Corp Derivados de purinona como agonistas de hm74a

Also Published As

Publication number Publication date
EP2049544A2 (de) 2009-04-22
WO2007150026A3 (en) 2008-02-21
JP2009541356A (ja) 2009-11-26
IL195896A0 (en) 2009-09-01
US7902205B2 (en) 2011-03-08
JP5274455B2 (ja) 2013-08-28
AU2007260852B2 (en) 2013-01-10
TWI423978B (zh) 2014-01-21
EP2049544B1 (de) 2010-11-03
US7863285B2 (en) 2011-01-04
DE602007010312D1 (de) 2010-12-16
US20090088446A1 (en) 2009-04-02
TW200811181A (en) 2008-03-01
NO20085099L (no) 2009-02-16
EP2049544B9 (de) 2011-07-20
US20090076269A1 (en) 2009-03-19
AR061626A1 (es) 2008-09-10
US20080045555A1 (en) 2008-02-21
KR20090025262A (ko) 2009-03-10
AU2007260852A1 (en) 2007-12-27
WO2007150026A2 (en) 2007-12-27
JP2013151513A (ja) 2013-08-08
CA2656002A1 (en) 2007-12-27
MX2009000169A (es) 2009-01-26
US7462624B2 (en) 2008-12-09

Similar Documents

Publication Publication Date Title
DE602007010312D1 (de) Purinonderivate als hm74a-agonisten
ATE487719T1 (de) Xanthinderivate als selektive hm74a-agonisten
IL195904A0 (en) Purinone derivatives as hm74a agonists
DK2016080T3 (da) Dihydropyrazolopyrimidinon-derivater
ATE483711T1 (de) Spiroindolinonderivate
ATE469905T1 (de) Pyridopyrimidinonderivate
ATE512135T1 (de) Spiroindolinonderivate
DK2035394T3 (da) 2-pyrazincarboxamidderivater
NL1031741A1 (nl) Purinederivaten.
NO20085127L (no) Leptomycinderivater
DK2277509T5 (da) DPP-IV-inhibitorformuleringer
EP2103613A4 (de) Chinoxalinderivat
EP2072519A4 (de) Diarylketiminderivat
BRPI0807911A2 (pt) Agonistas de alfa2c adrenorreceptor
ATE467623T1 (de) Diazepan-acetamidderivate als selektive 11-hsd1- hemmer
ATE545417T1 (de) Pyrazoloä3,4-büpyridin-derivate als phosphodiesterasehemmer
ATE544764T1 (de) 5-hydroxymethyloxazolidin-2-onderivate
CR10520A (es) Derivados de purina como agonistas de a2a
ATE537149T1 (de) Sulfonyl-pyrazolinyl-1-carboxamidinderivate als 5-ht6-antagonisten
ATE414085T1 (de) Purinderivate als a2a-rezeptoragonisten
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
FR2902426B1 (fr) Derives de cinnamoyl-piperazine
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
DK1971588T3 (da) Tiglien-3-onderivater

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties